DR. NELSON MARC KARP, MD
Marriage and Family Therapists at Independence Blvd, Virginia Beach, VA
License number
Virginia 0101034323
Category
Osteopathic Medicine
Type
Family Medicine
Address
Address
460 S Independence Blvd, Virginia Beach, VA 23452
Phone
(757) 497-3439
(757) 499-8702 (Fax)
(757) 499-8702 (Fax)
Professional information
Method Of Inducing An Immune Response In A Host By Administering Immunogenic Compositions Comprising Uv-Irradiated, Psoralen-Inactivated, Desialated Human Immunodeficiency Virus (Hiv) Particles Devoid Of Cd55 And Cd59 In The Viral Membrane
US Patent:
7700116, Apr 20, 2010
Filed:
Dec 5, 2008
Appl. No.:
12/315776
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
A61K 39/21, C12N 7/04
US Classification:
4242081, 435236
Abstract:
A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. A method of developing an immune response to HIV using a composition of inactivated HIV. Inactivation is through psoralen and ultraviolet radiation. The composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement factor H.
Animal Model For Hiv Induced Disease
US Patent:
2010027, Oct 28, 2010
Filed:
Jun 4, 2010
Appl. No.:
12/794102
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
A01K 67/00, C12N 7/00
US Classification:
800 11, 4352351
Abstract:
HIV does not cause disease in any non-human species. Thus, there is no animal model system to evaluate the efficacy of strategies aimed at preventing, treating or curing disease caused by this virus. The present invention provides compositions and a method for producing an animal model for HIV induced disease. The present invention is an animal adapted to simulate a human-like immune response to HIV, which is accomplished by activation and inactivation of complement of proteins within the animal. Accordingly, the present invention stages certain human proteins within an animal by way of its gut associated lymphoid tissue followed by infection of live HIV.
Methods Of Inducing Th-1 Immune Responses To Hiv-1 By Administering Uv/Psoralen-Treated Desialated Inactiviated Hiv-1 Virions Deficient In Cd55 And Cd59
US Patent:
7892562, Feb 22, 2011
Filed:
Oct 8, 2009
Appl. No.:
12/576055
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
A61K 39/21, C12N 7/06
US Classification:
4242081, 435238
Abstract:
Administration protocols for a fusion protein, matrix protein and psoralen inactivated HIV based immunogenic composition that induces an immune response to HIV. The immunogenic compositions are based on HIV biologically active fusion peptide, matrix peptide, or psoralen inactivated HIV. The number of doses is 3X. The starting dose for an adult is 1x10-1x10. The starting dose for an adolescent is ½(1x10-1x10). The starting dose for a pediatric patient is ¼(1x10-1x10). The second dose will consist of 1/10of starting concentrations. The third dose will consist of 1/100of starting concentrations. This will facilitate a Th-1 response. The days of administration are days 1; 30; and 180. Alternatively the days of administration are days 1; 20-40; and 160-200. The site of administration is one that targets lymphatic tissue. Adjuvant is administered before, simultaneous with or after each dose of the immunogenic compositions.
Immunizing Compositions Comprising Recombinant Attenuated Self-Replicating Viral Rna Replicons Encoding An Epitope Obtained From The Hiv-1 Matrix Protein Myrstate Binding Site
US Patent:
7790177, Sep 7, 2010
Filed:
Aug 27, 2008
Appl. No.:
12/229865
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
A61K 39/12, A61K 39/21, A61K 39/193, C07H 21/04
US Classification:
4241991, 4241881, 4242181, 536 2372
Abstract:
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Immunogenic Composition And Method Of Developing A Vaccine Based On Fusion Protein
US Patent:
2011010, May 5, 2011
Filed:
Nov 5, 2010
Appl. No.:
12/940390
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
A61K 39/21, A61P 31/18
US Classification:
4241921
Abstract:
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Method Of Developing An Immunogenic Composition And Hiv Vaccine
US Patent:
2005011, May 26, 2005
Filed:
Oct 22, 2004
Appl. No.:
10/971445
Inventors:
Nelson Karp - Virginia Beach VA, US
International Classification:
C12Q001/70, A61K039/12, A61K039/21
US Classification:
424199100, 424208100, 435005000
Abstract:
An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. Determination of strains for inactivation may be though immunotherapeutic genotyping or probabilistic assessment of risk of exposure.
Immunizing Compositions Encoding An Epitope Obtained From The Hiv-1 Capsid Protein Cyclophilin A Binding Site
US Patent:
7786288, Aug 31, 2010
Filed:
Oct 22, 2004
Appl. No.:
10/971199
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
C07H 21/04, A61K 39/21, A61K 39/12, A61K 39/02
US Classification:
536 2372, 4241881, 4241991, 4242001
Abstract:
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one binding site of Cyclophilin A on the HIV capsid protein. (SEQ ID NOS: 2, 4, and 6) The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NOS: 2, 4, and 6), messenger RNA, or DNA/RNA. DNA/RNA compositions (SEQ ID NOS 1, 3, 5, 7, 9, and 11) may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Immunogenic Composition And Method Of Developing A Vaccine Based On Fusion Protein
US Patent:
2005021, Sep 29, 2005
Filed:
Oct 22, 2004
Appl. No.:
10/971426
Inventors:
Nelson Karp - Virginia Beach VA, US
International Classification:
A61K039/21, A61K039/12
US Classification:
424188100, 424199100, 424200100
Abstract:
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Immunizing Compositions Comprising Nucleic Acids Encoding The Hiv-1 Matrix Protein Myristate Binding Site
US Patent:
7718180, May 18, 2010
Filed:
Aug 27, 2008
Appl. No.:
12/229863
Inventors:
Nelson M. Karp - Virginia Beach VA, US
International Classification:
A61K 39/21, A61K 45/00, C07H 21/04, C12N 15/00
US Classification:
4241881, 4242781, 536 2372, 4353201
Abstract:
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Treatment Of Blood With Light
US Patent:
2006027, Nov 30, 2006
Filed:
Aug 2, 2006
Appl. No.:
11/497789
Inventors:
Nelson Karp - Virginia Beach VA, US
International Classification:
A61M 37/00
US Classification:
604006080
Abstract:
A device for the exposure of blood to light produces a controlled, safe, and rapid exposure of blood to specific emissions, thereby inducing improved immune response. The device exposes the blood through a simplified macro blood flow path in which the internal or micro blood flow is in a spiral motion. The device includes a blood flow path, a pump, an exposure chamber, an ultraviolet light source, and a vacuum chamber.